nevirapine has been researched along with Thrombocythemia in 1 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thrombocytopenia was higher in children with WHO Stage III/IV, lower in children on zidovudine, and had no association with use of lamivudine or nevirapine, CD4 + suppression, age, and nutrition status." | 1.91 | Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy. ( Airewele, G; Bulsara, S; Despotovic, J; Elyanu, P; Grimes, A; Haq, H; Kekitiinwa, A; Kim, TO; Lubega, J; Lumumba, M; Matshaba, M; Musoke, P; Peckham, E; Scheurer, M; Wanless, SR, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lubega, J | 1 |
| Kim, TO | 1 |
| Airewele, G | 1 |
| Grimes, A | 1 |
| Bulsara, S | 1 |
| Peckham, E | 1 |
| Wanless, SR | 1 |
| Haq, H | 1 |
| Elyanu, P | 1 |
| Musoke, P | 1 |
| Lumumba, M | 1 |
| Kekitiinwa, A | 1 |
| Matshaba, M | 1 |
| Scheurer, M | 1 |
| Despotovic, J | 1 |
1 other study available for nevirapine and Thrombocythemia
| Article | Year |
|---|---|
Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Case-Control Studies; CD4 Lymphocyte Count; Child; HIV Infection | 2023 |